KR102464778B1 - 다중-리간드 약물 접합체 및 그의 용도 - Google Patents

다중-리간드 약물 접합체 및 그의 용도 Download PDF

Info

Publication number
KR102464778B1
KR102464778B1 KR1020207016784A KR20207016784A KR102464778B1 KR 102464778 B1 KR102464778 B1 KR 102464778B1 KR 1020207016784 A KR1020207016784 A KR 1020207016784A KR 20207016784 A KR20207016784 A KR 20207016784A KR 102464778 B1 KR102464778 B1 KR 102464778B1
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
cell
conjugate compound
ligand
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207016784A
Other languages
English (en)
Korean (ko)
Other versions
KR20200071152A (ko
Inventor
바오후아 로버트 후앙
지안 다이
쫑보 왕
쑤에위안 씨에
시아오동 리우
신리 후
Original Assignee
코히런트 바이오파마 I, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201510489556.6A external-priority patent/CN106466485B/zh
Priority claimed from CN201510489560.2A external-priority patent/CN106466484B/zh
Application filed by 코히런트 바이오파마 I, 리미티드 filed Critical 코히런트 바이오파마 I, 리미티드
Publication of KR20200071152A publication Critical patent/KR20200071152A/ko
Application granted granted Critical
Publication of KR102464778B1 publication Critical patent/KR102464778B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207016784A 2015-08-11 2016-08-11 다중-리간드 약물 접합체 및 그의 용도 Active KR102464778B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201510489556.6A CN106466485B (zh) 2015-08-11 2015-08-11 一种具有细胞内吞介导功能的靶向配体-药物偶联体
CN201510489560.2 2015-08-11
CN201510489556.6 2015-08-11
CN201510489560.2A CN106466484B (zh) 2015-08-11 2015-08-11 一种具有细胞内吞介导功能的多靶向配体-药物偶联体
PCT/CN2016/094704 WO2017025057A1 (en) 2015-08-11 2016-08-11 Multi-ligand drug conjugates and uses thereof
KR1020187003716A KR102301596B1 (ko) 2015-08-11 2016-08-11 다중-리간드 약물 접합체 및 그의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187003716A Division KR102301596B1 (ko) 2015-08-11 2016-08-11 다중-리간드 약물 접합체 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20200071152A KR20200071152A (ko) 2020-06-18
KR102464778B1 true KR102464778B1 (ko) 2022-11-07

Family

ID=57983917

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207016784A Active KR102464778B1 (ko) 2015-08-11 2016-08-11 다중-리간드 약물 접합체 및 그의 용도
KR1020187003716A Active KR102301596B1 (ko) 2015-08-11 2016-08-11 다중-리간드 약물 접합체 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187003716A Active KR102301596B1 (ko) 2015-08-11 2016-08-11 다중-리간드 약물 접합체 및 그의 용도

Country Status (13)

Country Link
US (2) US11571480B2 (https=)
EP (1) EP3334500B1 (https=)
JP (3) JP6772199B2 (https=)
KR (2) KR102464778B1 (https=)
CN (3) CN112263683A (https=)
AU (2) AU2016305703B2 (https=)
CA (1) CA2987322C (https=)
DK (1) DK3334500T3 (https=)
ES (1) ES2877409T3 (https=)
MX (1) MX381031B (https=)
RU (1) RU2722449C2 (https=)
WO (1) WO2017025057A1 (https=)
ZA (1) ZA201707464B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2445932B1 (en) 2009-06-26 2018-02-28 Soricimed Biopharma Inc. Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
JP6772199B2 (ja) * 2015-08-11 2020-10-21 コヒレント バイオファーマ 多リガンド−薬物複合体及びその使用
CA3083950A1 (en) * 2017-12-01 2019-06-06 Soricimed Biopharma Inc. Trpv6 inhibitors and combination therapies for treating cancers
US11576981B2 (en) 2017-12-06 2023-02-14 Ontario Institute For Cancer Research (Oicr) Acyl hydrazone linkers, methods and uses thereof
WO2019119141A1 (en) 2017-12-22 2019-06-27 Ontario Institute For Cancer Research (Oicr) Heterocyclic acyl hydrazone linkers, methods and uses thereof
WO2019134018A1 (en) * 2018-01-05 2019-07-11 Telethon Kids Institute Vaccine conjugates and uses thereof
AU2020214507B2 (en) * 2019-01-30 2025-09-25 Coherent Biopharma (Suzhou), Limited Bi-ligand drug conjugate and use thereof
WO2021016392A1 (en) * 2019-07-22 2021-01-28 Purdue Research Foundation Multivalent fibroblast-targeted agents and methods of use
CN114286867B (zh) * 2019-08-20 2024-04-16 青岛华大智造科技有限责任公司 一种基于发光标记物光信号动力学及二次发光信号对多核苷酸进行测序的方法
WO2021163701A1 (en) * 2020-02-13 2021-08-19 Escape Therapeutics, Inc. Melanoma therapeutics
EP4274595A4 (en) * 2021-01-07 2026-01-21 Purdue Research Foundation FOLATE RECEPTOR-TARGETED CONJUGATES, COMPOSITIONS AND ADMINISTRATION TO THE CENTRAL NERVOUS SYSTEM
CN117693365A (zh) * 2021-06-25 2024-03-12 同宜医药（苏州）有限公司 配体药物偶联物及其应用
CN116059392B (zh) * 2021-09-03 2025-02-28 同宜医药（苏州）有限公司 配体偶联物及其应用
JP2024533395A (ja) * 2021-09-08 2024-09-12 同宜医藥（蘇州）有限公司 薬物製剤及びその製造方法と用途
TW202327659A (zh) * 2021-10-19 2023-07-16 大陸商同宜醫藥（蘇州）有限公司 偶聯體藥物製劑及其製備方法和用途
CN116196408B (zh) * 2021-12-30 2026-01-06 思格(苏州)生物科技有限公司 一种新型免疫佐剂及其制备方法和应用
TW202404643A (zh) * 2022-04-20 2024-02-01 大陸商同宜醫藥（蘇州）有限公司 化合物及用途
WO2024099387A1 (zh) * 2022-11-09 2024-05-16 同宜医药（苏州）有限公司 通过施用配体-药物偶联体治疗癌症
CN120813385A (zh) * 2023-03-23 2025-10-17 同宜医药（苏州）有限公司 通过施用配体-药物偶联体治疗卵巢癌
WO2024222803A1 (zh) * 2023-04-26 2024-10-31 同宜医药（苏州）有限公司 一种配体-药物偶联体在治疗癌症中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015106599A1 (en) 2014-01-20 2015-07-23 Brightgene Bio-Medical Technology Co., Ltd. Conjugates and compositions for drug delivery

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
AU2002337954C1 (en) 2001-10-22 2008-10-23 The Scripps Research Institute Integrin targeting compounds
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
GB0209893D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7119168B2 (en) 2002-11-18 2006-10-10 Bioprospecting Nb Inc. Paralytic peptide for use in neuromuscular therapy
EP1689443B1 (en) 2003-12-05 2019-03-13 Arrogene, Inc. Polymalic acid-based multifunctional drug delivery system
WO2006060664A2 (en) 2004-12-03 2006-06-08 The Uab Research Foundation Single-drug multi-ligand conjugates for targeted drug delivery
BRPI0615354A2 (pt) 2005-08-19 2011-05-17 Endocyte, Inc. conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
EP2354163A3 (en) 2005-09-26 2013-04-24 Medarex, Inc. Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies
JP2010503708A (ja) * 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド 多官能性リンカーを含む標的化ポリマープロドラッグ
US20080181852A1 (en) 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101224306B (zh) * 2008-02-20 2011-04-20 中山大学 叶酸-多肽复合物介导的靶向抗肿瘤前体药物及其制备方法
EP2362729A1 (en) 2008-11-17 2011-09-07 Enzon Pharmaceuticals, Inc. Releasable conjugates for nucleic acids delivery systems
WO2010059315A1 (en) * 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US9572895B2 (en) 2010-08-06 2017-02-21 The Board Of Trustees Of The University Of Illinois Multiplexed supramolecular assemblies for non-viral delivery of genetic material
IN2014DN00101A (https=) 2011-06-06 2015-05-15 Starpharma Pty Ltd
JP6355563B2 (ja) * 2012-02-27 2018-07-11 アムニクス オペレーティング インコーポレイテッド Ｘｔｅｎ共役組成物およびそれを製造する方法
CN103372199B (zh) * 2012-04-16 2015-12-16 广州暨南大学医药生物技术研究开发中心 一种预防和治疗神经退行性疾病的新型脑部靶向制剂
CA2873112A1 (en) 2012-05-11 2013-11-14 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
GB201211309D0 (en) 2012-06-26 2012-08-08 Fujifilm Mfg Europe Bv Process for preparing membranes
CN104411337A (zh) 2012-07-09 2015-03-11 基因泰克公司 包含抗cd79b抗体的免疫偶联物
ES2781523T3 (es) * 2012-07-12 2020-09-02 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
WO2014089209A2 (en) 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
EP2928502B1 (en) 2012-12-05 2019-01-23 Ruprecht-Karls-Universität Heidelberg Conjugates of proteins and multivalent cell-penetrating peptides and their uses
US10150800B2 (en) * 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
AU2014337317A1 (en) 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
CN104667292B (zh) * 2015-02-02 2017-09-05 北京大学 一种还原响应型药物偶联物纳米粒的制备及其应用
EP3294810A4 (en) * 2015-05-12 2019-01-02 Blinkbio Inc. Silicon based drug conjugates and methods of using same
JP6772199B2 (ja) * 2015-08-11 2020-10-21 コヒレント バイオファーマ 多リガンド−薬物複合体及びその使用
JP2020164335A (ja) * 2019-03-28 2020-10-08 イビデン株式会社 ハニカム構造体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015106599A1 (en) 2014-01-20 2015-07-23 Brightgene Bio-Medical Technology Co., Ltd. Conjugates and compositions for drug delivery

Also Published As

Publication number Publication date
WO2017025057A1 (en) 2017-02-16
HK1250634A1 (zh) 2019-01-11
MX2018001723A (es) 2018-05-17
JP2018529632A (ja) 2018-10-11
CA2987322A1 (en) 2017-02-16
KR20180033513A (ko) 2018-04-03
EP3334500A4 (en) 2019-04-03
AU2019240611B2 (en) 2021-09-09
US11571480B2 (en) 2023-02-07
CN108135881A (zh) 2018-06-08
JP6772199B2 (ja) 2020-10-21
JP7573401B2 (ja) 2024-10-25
EP3334500B1 (en) 2021-04-07
ZA201707464B (en) 2021-05-26
KR20200071152A (ko) 2020-06-18
AU2016305703A1 (en) 2017-11-23
RU2018104266A (ru) 2019-09-12
CN108135881B (zh) 2020-11-13
EP3334500A1 (en) 2018-06-20
ES2877409T3 (es) 2021-11-16
RU2018104266A3 (https=) 2019-09-12
CA2987322C (en) 2020-02-11
RU2722449C2 (ru) 2020-06-01
US20240100175A1 (en) 2024-03-28
CN111617250A (zh) 2020-09-04
JP2021006549A (ja) 2021-01-21
KR102301596B1 (ko) 2021-09-14
AU2019240611A1 (en) 2019-10-17
AU2016305703B2 (en) 2019-07-25
MX381031B (es) 2025-03-12
CN111617250B (zh) 2022-07-01
CN112263683A (zh) 2021-01-26
US20180200377A1 (en) 2018-07-19
JP2023025151A (ja) 2023-02-21
DK3334500T3 (da) 2021-06-21

Similar Documents

Publication Publication Date Title
KR102464778B1 (ko) 다중-리간드 약물 접합체 및 그의 용도
CN113453720B (zh) 双配体药物偶联体及其用途
CN109513010B (zh) 肿瘤细胞特异性响应的自组装药物纳米缀合物
HK40036786A (en) Multi-ligand drug conjugates and uses thereof
HK40036786B (zh) 多配体药物偶联体及其用途
KR20230085578A (ko) 암 예방 또는 치료를 위한 알부민 결합 전구약물, 이를 포함하는 약학 조성물
HK1250634B (zh) 多配体药物偶联体及其用途
HK1253921B (en) Multi-ligand drug conjugates and uses thereof
RU2820346C2 (ru) Билигандный конъюгат лекарственного средства и его применение
HK40052006A (en) Bi-ligand drug conjugate and use thereof
HK40061762A (en) Bi-ligand drug conjugate and use thereof
CN116390938A (zh) 毒蜥外泌肽-4类似物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4